EUSA Pharma - Healthcare Professional Website - Sylvant

ABOUT CASTLEMAN’S DISEASE

The Castleman Disease Collaborative Network (CDCN)
https://cdcn.org

National Institutes of Health, Genetic and Rare Disease Information Center:

Multicentric Castleman disease:
https://rarediseases.info.nih.gov/diseases/9644/multicentric-castleman-disease

ABOUT SYLVANT®

European Medicines Agency, SYLVANT® overview and product information:
https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant

ABOUT EUSA PHARMA

EUSA Pharma, including local contact details for medical information:
https://www.eusapharma.com/

Diagnosis

Idiopathic Multicentric Castleman Disease (iMCD) is a rare and devasting disease

Efficacy

Pivotal Phase 2 Study

Tolerability

Adverse reactions and safety

Mode of Action

Understanding the mechanism of action of SYLVANT®

Dosing & Administration

Recommended dosing of SYLVANT®

Clinical Papers

Request published clinical papers

Join our mailing list
Enter your email to receive email alerts when new content is added to this website

This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.

© 2020 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ

Useful Links